Internal Medicine, Cardiovascular Disease · San Antonio, TX
NPI
1902998347
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
502 Madison Oak, Suite 310
San Antonio, TX, 78258
Phone (210) 483-8883
Groups this clinician bills Medicare through
Medicare paid, 2024
$517K
8,388 services
Medicare patients, 2024
2,031
Average age 76
Drug cost, 2024
$2.1M
10,537 prescriptions
Company payments, 2025
$2,176
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark F Colligan was code 99214 (office e&m - established), 2,276 times for 1,501 patients. In total Mark F Colligan billed 8,388 services in 63 codes, and Medicare paid $517K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-12-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 2,276 | 1,501 | $84.70 | $193K |
| 93000 Electrocardiogram | Office | 792 | 766 | $10.03 | $7,943 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 783 | 598 | $12.39 | $9,701 |
| 99232 Hospital E&M - Subsequent | Facility | 588 | 192 | $59.38 | $35K |
| 93306 Echocardiography (TTE/TEE) | Office | 503 | 486 | $129.41 | $65K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 461 | 116 | $5.18 | $2,387 |
| 93294 External Electrocardiographic Monitoring | Office | 410 | 140 | $18.99 | $7,787 |
| 99204 Office E&M - New | Office | 331 | 331 | $110.20 | $36K |
| 93297 External Electrocardiographic Monitoring | Office | 300 | 41 | $17.70 | $5,309 |
| 93015 Electrocardiogram | Office | 238 | 237 | $46.17 | $11K |
| 93298 External Electrocardiographic Monitoring | Office | 237 | 42 | $16.50 | $3,912 |
| 93306 Echocardiography (TTE/TEE) | Facility | 204 | 198 | $49.20 | $10K |
| 99223 Hospital E&M - Initial | Facility | 176 | 164 | $126.30 | $22K |
| A9500 Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 171 | 167 | $46.91 | $8,022 |
| 78452 Myocardial Perfusion Scan | Office | 169 | 169 | $314.41 | $53K |
By year: 2022 $490K for 7,174 services; 2023 $477K for 6,657 services; 2024 $517K for 8,388 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 91 | 13 | $4.20 | $382 |
| 36415 Venipuncture Blood Collection | 16 | 15 | $8.40 | $134 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark F Colligan prescribed most often to Medicare patients was Amlodipine Besylate, with 935 prescriptions and refills. In total Mark F Colligan wrote 10,537 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 935 | 2,511 | 284 | $5,030 |
| Eliquis Apixaban | 846 | 1,798 | 203 | $1.0M |
| Rosuvastatin Calcium Generic | 820 | 2,348 | 265 | $10K |
| Atorvastatin Calcium Generic | 607 | 1,734 | 196 | $5,471 |
| Carvedilol Generic | 550 | 1,597 | 180 | $4,383 |
| Losartan Potassium Generic | 544 | 1,516 | 184 | $5,638 |
| Metoprolol Succinate Generic | 522 | 1,475 | 167 | $7,851 |
| Ezetimibe Generic | 444 | 1,298 | 151 | $11K |
| Metoprolol Tartrate Generic | 414 | 1,184 | 129 | $3,381 |
| Chlorthalidone Generic | 393 | 1,081 | 129 | $7,348 |
| Lisinopril Generic | 329 | 985 | 105 | $2,455 |
| Xarelto Rivaroxaban | 327 | 776 | 88 | $415K |
| Olmesartan Medoxomil Generic | 298 | 789 | 99 | $4,679 |
| Spironolactone Generic | 253 | 673 | 95 | $1,990 |
| Torsemide Generic | 217 | 461 | 76 | $3,599 |
Brand drugs: 1,731 claims; generic drugs: 8,806 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark F Colligan $2,176 ($2,176 in general payments such as food, travel and fees) from 9 companies. The largest payer was Novartis Pharmaceuticals Corporation with $521.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 28 | $521 |
| Medtronic, Inc. MDT | 3 | $384 |
| Abbott Laboratories ABT | 7 | $349 |
| E.R. Squibb & Sons, L.L.C. BMY | 28 | $285 |
| Pfizer Inc. PFE | 20 | $213 |
| Amgen Inc. AMGN | 4 | $184 |
| Shockwave Medical, Inc JNJ | 2 | $134 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63.38 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 6 | $42.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.